Misleading Advertising for Antidepressants in Sweden: A Failure of Pharmaceutical Industry Self-Regulation

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Zetterqvist, Anna V ^a   Mulinari, Shai ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUOXETINE SELENA; FLUVOXAMINE; FLUVOXAMINE MALEATE; MIRTAZAPINE; MOCLOBEMIDE; NEFAZODON; NEFAZODONE; PAROXETINE; REBOXETINE; SEROSCAND FLUOXETINE; SERTRALINE; UNCLASSIFIED DRUG; VENLAFAXINE;

ARTICLE; DEPRESSION; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MARKETING; LEGAL ASPECT; MEDICAL LITERATURE; PREVALENCE; SWEDEN; ADVERTIZING; ECONOMICS; ETHICS; FRAUD; HUMAN; LEGISLATION AND JURISPRUDENCE; PUBLICATION; SOCIAL CONTROL;

ADVERTISING AS TOPIC; ANTIDEPRESSIVE AGENTS; DRUG INDUSTRY; FRAUD; HUMANS; LEGISLATION, DRUG; PERIODICALS AS TOPIC; SOCIAL CONTROL, INFORMAL; SWEDEN;

EID: 84877016094     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062609     Document Type: Article

References (63)

1. Fugh-Berman A, Alladin K, Chow J, (2006) Advertising in medical journals: Should current practices change? PLoS Med 3 762-768: e130 doi:10.1371/journal.pmed.0030130.
2. Simmonds H, (2003) Drug advertising in medical journals. Lancet 361: 878-879.
3. International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) (2012) Self-Regulation of Pharmaceutical Promotion. Available: http://www.ifpma.org/ethics/ifpma-code-of-practice/about-ifpma-code-of-practice.html. Accessed 28 May 2012.
4. Villanueva P, Peiró S, Librero J, Pereiró I, (2003) Accuracy of pharmaceutical advertisements in medical journals. Lancet 361: 27-32.
5. van Winkelen P, van Denderen JS, Vossen CY, Huizinga TWJ, Dekker FW, et al. (2006) How evidence-based are advertisements in journals regarding the subspecialty of rheumatology? Rheumatology 45: 1154-1157.
6. Heimans L, Vlieg AV, Dekker FW, (2010) Are claims of advertisements in medical journals supported by RCTs? Neth J Med 68: 46-49.
7. Othman N, Vitry AI, Roughead EE, (2010) Quality of claims, references and the presentation of risk results in medical journal advertising: a comparative study in Australia, Malaysia and the United States. BMC Public Health 10: 294 doi:10.1186/1471-2458-10-294.
8. Korenstein D, Keyhani S, Mendelson A, Ross JS, (2011) Adherence of pharmaceutical advertisements in medical journals to FDA guidelines and content for safe prescribing. PLoS One 6: e23336 doi:10.1371/journal.pone.0023336.
9. Othman N, Vitry A, Roughead EE, (2009) Quality of pharmaceutical advertisements in medical journals: A systematic review. PLoS One 4: e6350 doi:10.1371/journal.pone.0006350.
10. Lexchin J, (2010) Statistics in drug advertising: what they reveal is suggestive what they hide is vital. Int J Clin Pract 64: 1015-1018.
11. Spielmans GI, Thielges SA, Dent AL, Greenberg RP, (2008) The accuracy of psychiatric medication advertisements in medical journals. J Nerv Ment Dis 196: 267-273.
12. Lankinen KS, Levola T, Marttinen K, Puumalainen I, Helin-Salmivaara A, (2004) Industry guidelines, laws and regulations ignored: quality of drug advertising in medical journals. Pharmacoepidemiol Drug Saf 13: 789-795.
13. Lal A, Moharana AK, Srivastava S, (1997) Comparative evaluation of drug advertisements in Indian, British and American medical journals. J Indian Med Assoc 95: 19-20.
14. Charan J, Yadav P, Saxena D, Kantharia ND, (2011) Drug advertisements published in Indian Medical Journals: Are they ethical? J Pharm Bioallied Sci 3: 403-406.
15. Spurling GK, Mansfield PR, Montgomery BD, Lexchin J, Doust J, et al. (2010) Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: A systematic review. PLoS Med 7: e1000352 doi:10.1371/journal.pmed.1000352.
16. Perman E, (1990) Voluntary control of drug promotion in Sweden. N Engl J Med 323: 616-617.
17. Herxheimer A, Collier J, (1990) Promotion by the British pharmaceutical industry. 1983-8- A critical analysis of self regulation. BMJ 300: 307-311.
18. Lexchin J, (1997) Enforcement of codes governing pharmaceutical promotion: What happens when companies breach advertising guidelines? CMAJ 156: 351-356.
19. Lexchin J, (2003) Voluntary self-regulatory codes: What should we expect? Am J Bioeth 3: 49-50.
20. Mulinari S (2012) Regulating drug information in Europe: a phyrric victory for pharmaceutical industry critics? Sociol Health Illn. doi: 10.1111/j.1467-9566.2012.01528.x.
21. European Federation of Pharmaceutical Industries and Associations (2008) EFPIA contribution to the European Commission public consultation on a legal proposal on information to patients. Brussels: EFPIA. 13 p.
22. High Level Pharmaceutical Forum (2008) Final conclusions and recommendations of the Pharmaceutical Forum. Brussels: Pharmaceutical Forum. 130 p.
23. House of Commons Health Committee (2005) The Influence of the pharmaceutical industry: Health Select Committee Report Volume 2. London: The stationery office limited. 550 p.
24. Lynch R, Kupiec R, (2005) Worldwide survey on national controls of pharmaceutical advertising and promotion. Regulatory Rapporteur 2: 7-10.
25. Ratanawijitrasin S, Wondemagegnehu E (2002) Effective drug regulation: A multicountry study. Geneva: World Health Organization. 202 p.
26. Swedish Association of the Pharmaceutical Industry (LIF) (2011) Ethical rules for the pharmaceutical industry in Sweden. Avaialble: www.lif.se/default.aspx?id=63542. Accessed 28 May 2012.
27. European Federation of Pharmaceutical Industries and Associations (EFPIA) (2012) EFPIA code on the promotion of prescription-only medicines to, and interaction with, healthcare professionals. Avaialble: http://www.efpia.eu/content/default.asp?PageID=366. Accessed 28 May 2012.
28. International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) (2012) IFPMA Code of Practice. Available: http://www.ifpma.org/ethics/ifpma-code-of-practice/ifpma-code-of-practice.html. Accessed 28 May 2012.
29. Huskamp HA, Donohue JM, Koss C, Berndt ER, Frank RG, (2008) Generic entry, reformulations and promotion of SSRIs in the US. Pharmacoeconomics 26: 603-16.
30. Läkartidningen [Swedish Medical Journal] (2012) Homepage. Available: http://www.lakartidningen.se/. Accessed 28 May 2012.
31. Läkartidningen [Swedish Medical Journal] (2012) Produktannonser [Product ads]. Available: http://www.lakartidningen.se/pdf/2012_pris/produkt_2012.pdf.
32. Swedish Association of the Pharmaceutical Industry (LIF) (2012) IGM/NBL Database. Available: http://www.lif.se/default.aspx?id=19143. Accessed 15 September 2012.
33. Melander H, Salmonson T, Abadie E, van Zwieten-Boot B, (2008) A regulatory Apologia- a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants. Eur Neuropsychopharmacol 18: 623-627.
34. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R, (2008) Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 358: 252-260.
35. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, et al. (2008) Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 5: e45 doi:10.1371/journal.pmed.0050045.
36. National Institute for Clinical Excellence (NICE) (2004) Depression: management of depression in primary and secondary care- NICE guidelines. Available: www.nice.org.uk/nicemedia/pdf/cg023fullguideline.pdf. Accessed 28 May 2012.
37. Swedish Association of the Pharmaceutical Industry (LIF) (2011) Formulating an advertisement according to the Ethical rules for the pharmaceutical industry. Stockholm: LIF. 9 p.
38. Healy D (1997) The antidepressant era. Cambridge, Mass.: Harvard University Press. 305 p.
39. Lacasse JR, Leo J, (2005) Serotonin and depression: a disconnect between the advertisements and the scientific literature. PLoS Med 2: e392 doi:10.1371/journal.pmed.0020392.
40. Shorter E (2009) Before Prozac: the troubled history of mood disorders in psychiatry. Oxford: Oxford University Press. 304 p.
41. Mulinari S, (2012) Monoamine theories of depression: historical impact on biomedical research. J Hist Neurosci 23: 366-392.
42. Mendels J, Frazer A, (1974) Brain biogenic amine depletion and mood. Arch Gen Psychiatry 30: 447-451.
43. Healy D, Paykel ES (1992) Neurochemistry of Mood Disorders. In: Asbury AK, McKhann GM, McDonald WI, editors. Diseases of the nervous system: clinical neurobiology Vol 1. 2 ed. Philadelphia: Saunders. 815-830.
44. Duman RS, Heninger GR, Nestler EJ, (1997) A molecular and cellular theory of depression. Arch Gen Psychiatry 54: 597-606.
45. The Swedish Pharmaceutical Industry Information Examiner (IGM) (2012) Bi-annual reports 1994-2003. Available: http://www.lif.se/default.aspx?id=6614. Accessed 28 May 2012.
46. Apoteksbolaget (1991-2000) Svensk Läkemedelsstatistik [Swedish Medicines Statistics]. Annual reports. Stockholm: Apoteksbolaget.
47. Apoteket Service AB (2012) Available: http://www.apotekensservice.se/Om_statistik/.Accessed 28 May 2012.
48. The Swedish Riksbank (2012) Annual average exchange rates. Available: http://www.riksbank.se/sv/Rantor-och-valutakurser/Arsgenomsnitt-valutakurser/?y=1993&m=2&s=Comma. Accessed 28 May 2012.
49. Liebman M, (2000) Listen up, publishers say- journal advertising sells. Medical marketing & media 35: 88.
50. Olfson M, Marcus SC, (2009) National patterns in antidepressant medication treatment. Arch Gen Psychiatry 66: 848-56.
51. Ilyas S, Moncrieff J, (2012) Trends in prescriptions and costs of drugs for mental disorders in England, 1998-2010. BJP 200: 393-398 doi:10.1192/bjp.bp.111.10425752.
52. Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B, (2003) Evidence b(i)ased medicine- selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ 326: 1171-1173.
53. Mulinari S, (2011) Varför fara med osanning om depressioners orsaker? [Why lie about the causes of depression?]. Läkartidningen [Swedish Medical Journal] 108: 1839-40.
54. Andrée B, (2012) Serotoninhypotesen är en av flera förklaringsmodeller för depression och ångest [The serotonin hypothesis is one of several explanatory models of depression and anxiety]. Läkartidningen [Swedish Medical Journal] 109: 2106-7.
55. O'Brien C (2003 October 5) Drug firm to drop non-addiction claim. Irish Times.
56. United States Government Accountability Office (GAO) (2006) Improvements needed in FDA's oversight of direct-to-consumer advertising. Available: http://www.gao.gov/products/GAO-07-54. Accessed 11 September 2012.
57. Lexchin J, (2012) Models for financing the regulation of pharmaceutical promotion. Globalization and Health 8: 24 doi:10.1186/1744-8603-8-24.
58. The Swedish Pharmaceutical Industry Information Examiner (IGM) (2012) Bi-annual report IGM 2011: second half-year. Available: http://www.lif.se/default.aspx?id=6614. Accessed 28 May 2012.
59. Håkansson J, (2001) Årets bästa annons eller årets bottennapp [The year's best ad or the year's flop]? Läkartidningen [Swedish Medical Journal] 98: 1834.
60. Lennholm B, (2001) Tävling om bästa annons avgjord [Competition for the best ad decided]. Läkartidningen [Swedish Medical Journal] 98: 923.
61. Roughhead EE, (1999) The Australian Pharmaceutical Manufacturers Association Code of Conduct: guiding the promotion of prescription medicines. Australian Prescriber 22: 78-80.
62. Ruff TA, Haikal-Muhktar H, (2005) Doctors, drugs, information and ethics: a never-ending story. Medical Journal of Australia 183: 73-74.
63. Coombes R, (2005) Drug industry's new code criticised for lacking teeth. BMJ 331: 1225.